IN8bio, Inc. (INAB)
1.09
-0.05
(-4.39%)
USD |
NASDAQ |
Sep 09, 13:39
IN8bio Shareholders Equity (Quarterly) : 18.36M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 18.36M |
| March 31, 2026 | 22.78M |
| December 31, 2025 | 27.56M |
| September 30, 2025 | 13.19M |
| June 30, 2025 | 15.24M |
| March 31, 2025 | 13.88M |
| December 31, 2024 | 14.48M |
| September 30, 2024 | 8.588M |
| June 30, 2024 | 13.62M |
| March 31, 2024 | 17.53M |
| December 31, 2023 | 24.94M |
| Date | Value |
|---|---|
| September 30, 2023 | 17.76M |
| June 30, 2023 | 21.80M |
| March 31, 2023 | 16.79M |
| December 31, 2022 | 22.73M |
| September 30, 2022 | 29.56M |
| June 30, 2022 | 26.57M |
| March 31, 2022 | 32.84M |
| December 31, 2021 | 38.18M |
| September 30, 2021 | 43.04M |
| June 30, 2021 | |
| March 31, 2021 | 16.32M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 465.53M |
| Oncolytics Biotech, Inc. | -6.167M |
| Sangamo Therapeutics, Inc. | -18.96M |
| Sarepta Therapeutics, Inc. | 1.528B |
| Anixa Biosciences, Inc. | 14.48M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 21.74M |
| Total Liabilities (Quarterly) | 3.382M |
| Debt to Equity Ratio | 0.1186 |
| Current Ratio | 8.206 |
| Net Debt Paydown Yield | 3.02% |